Robert I Blum Cytokinetics Inc (CYTK) insider trading activity

Robert I Blum is President & CEO of CYTOKINETICS INC. Currently has a direct ownership of 427,629 shares of CYTK, which is worth approximately $18.5 Million. The most recent transaction as insider was on Mar 08, 2021, when has been sold 23,799 shares (Common Stock) at a price of $19.19 per share, resulting in proceeds of $456,703. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 428K

6.02% 3M change

7.28% 12M change

Total Value Held $18.5 Million

Robert I Blum Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 08 2021	SELL Payment of exercise price or tax liability	$456,703 $19.19 p/Share	23,799 Reduced 6.25%	356,859 Common Stock
Mar 08 2021	SELL Open market or private sale	$97,450 $19.49 p/Share	5,000 Reduced 1.3%	380,658 Common Stock
Mar 08 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.28%	385,658 Common Stock
Mar 02 2021	BUY Grant, award, or other acquisition	-	80,000 Added 17.37%	380,658 Common Stock
Mar 01 2021	SELL Payment of exercise price or tax liability	$194,949 $19.66 p/Share	9,916 Reduced 3.19%	300,658 Common Stock
Feb 26 2021	SELL Payment of exercise price or tax liability	$445,755 $18.73 p/Share	23,799 Reduced 7.12%	310,574 Common Stock
Feb 26 2021	SELL Open market or private sale	$96,650 $19.33 p/Share	5,000 Reduced 1.47%	334,373 Common Stock
Feb 26 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.45%	339,373 Common Stock
Feb 18 2021	SELL Payment of exercise price or tax liability	$1,146,053 $21.01 p/Share	54,548 Reduced 14.03%	334,373 Common Stock
Feb 18 2021	BUY Exercise of conversion of derivative security	$784,987 $9.42 p/Share	83,332 Added 17.9%	382,269 Common Stock
Feb 10 2021	SELL Open market or private sale	$119,400 $23.88 p/Share	5,000 Reduced 1.61%	305,589 Common Stock
Feb 10 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.58%	310,589 Common Stock
Jan 29 2021	SELL Open market or private sale	$101,700 $20.34 p/Share	5,000 Reduced 1.61%	305,589 Common Stock
Jan 29 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.58%	310,589 Common Stock
Jan 20 2021	SELL Open market or private sale	$102,050 $20.41 p/Share	5,000 Reduced 1.61%	305,589 Common Stock
Jan 20 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.58%	310,589 Common Stock
Jan 04 2021	SELL Open market or private sale	$101,150 $20.23 p/Share	5,000 Reduced 1.61%	305,589 Common Stock
Jan 04 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.58%	310,589 Common Stock
Dec 16 2020	SELL Open market or private sale	$102,550 $20.51 p/Share	5,000 Reduced 1.61%	305,589 Common Stock
Dec 16 2020	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.58%	310,589 Common Stock
Dec 04 2020	SELL Open market or private sale	$86,800 $17.36 p/Share	5,000 Reduced 1.61%	305,589 Common Stock
Dec 04 2020	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.58%	310,589 Common Stock
Nov 23 2020	SELL Open market or private sale	$78,650 $15.73 p/Share	5,000 Reduced 1.61%	304,868 Common Stock
Nov 23 2020	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.59%	309,868 Common Stock
Nov 10 2020	SELL Open market or private sale	$82,500 $16.5 p/Share	5,000 Reduced 1.61%	304,868 Common Stock

Also insider at

GMDA

Gamida Cell Ltd. Healthcare

Director

RIB

Robert I Blum

President & CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Value

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK

Account